Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors

Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors

Background: We aimed to characterize γ-H2AX and 53BP1 foci formation in patients receiving somatostatin receptor-targeted radioligand therapy, and explored its role for predicting treatment-related hematotoxicity, and treatment response. Methods: A prospective analysis of double-strand break (DSB) m...

Full description

Bibliographic Details
Main Authors:	Thorsten Derlin, Natalia Bogdanova, Fiona Ohlendorf, Dhanya Ramachandran, Rudolf A. Werner, Tobias L. Ross, Hans Christiansen, Frank M. Bengel, Christoph Henkenberens
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Cancers
Subjects:	neuroendocrine tumors double-strand breaks γ-H2AX 53BP1 radionuclide therapy PRRT
Online Access:	https://www.mdpi.com/2072-6694/13/7/1516

Similar Items

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
by: Fiona Ohlendorf, et al.
Published: (2021-03-01)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
by: Baptiste Camus, et al.
Published: (2021-03-01)

INCREASED FORMATION OF PHOSPHORYLATED H2AX FOCI IN NUCLEI OF CELLS INFECTED BY HEPATITIS B AND B+D VIRUSES
by: D. S. Kostyushev, et al.
Published: (2018-08-01)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
by: Anna Yordanova, et al.
Published: (2020-11-01)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
by: Virginia Liberini, et al.
Published: (2020-12-01)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
by: Mengqi Shi, et al.
Published: (2022-12-01)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
by: Christina-Katharina Fodi, et al.
Published: (2022-04-01)

Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now
by: Mitesh Naik, et al.
Published: (2022-02-01)

Immunocytochemical Localization of XRCC1 and γH2AX Foci Induced by Tightly Focused Femtosecond Laser Radiation in Cultured Human Cells
by: Alexandr Zalessky, et al.
Published: (2021-07-01)

Senescence-Associated Heterochromatin Foci Suppress γ-H2AX Focus Formation Induced by Radiation Exposure
by: Takashi Oizumi, et al.
Published: (2024-03-01)

Disintegration and context processing in AX-CPT
by: Šoljaga Mina, et al.
Published: (2023-01-01)

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
by: Kevin Zwirtz, et al.
Published: (2022-06-01)

Editorial: xCoAx 2020
by: André Rangel, et al.
Published: (2020-12-01)

Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review
by: Stefan Prado-Wohlwend, et al.
Published: (2022-10-01)

The Crystal Structure Elucidation of a Tetrapeptide Analog of Somatostatin DOTA-Phe-D-Trp-Lys-Thr-OMe
by: Sabina Diusenova, et al.
Published: (2021-12-01)

Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
by: Ulrika Jahn, et al.
Published: (2021-02-01)

Investigation of Auger Electron Emitting Radionuclides Effects in Therapy Using the Geant4-DNA Toolkit: A Simulation Study
by: Parvin Ahmadi, et al.
Published: (2021-06-01)

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
by: Ulrika Jahn, et al.
Published: (2023-05-01)

Bystander Response Following High-Dose X-irradiation; Time-dependent Nature of GammaH2AX Foci and Cell Death Consequences
by: Fatemeh Pakniyat, et al.
Published: (2023-02-01)

Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE
by: Amir Sabet, et al.
Published: (2021-10-01)

Simultaneous effect of gamma and Wi-Fi radiation on gamma-H2Ax expression in peripheral blood of rat: A radio-protection note
by: Ehsan Khodamoradi, et al.
Published: (2022-07-01)

Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead
by: Stephan Walrand, et al.
Published: (2021-08-01)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
by: Valentina Ambrosini, et al.
Published: (2022-02-01)

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
by: Pedro Marques
Published: (2023-05-01)

Cutaneous Management after Extravasation of High-Concentrated Amino Acid Solution Administered for Renal Protection in PRRT
by: Chaninart Sakulpisuti, et al.
Published: (2022-02-01)

A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
by: Daphne M. V. Huizing, et al.
Published: (2020-06-01)

γ-H2AX Foci Persistence at Chromosome Break Suggests Slow and Faithful Repair Phases Restoring Chromosome Integrity
by: Michelle Ricoul, et al.
Published: (2019-09-01)

Detection of rare blood group Ax phenotype in blood donor
by: Rakesh Kumar, et al.
Published: (2021-01-01)

A Performance Analysis of IEEE 802.11ax Networks
by: Marek Natkaniec, et al.
Published: (2020-02-01)

Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis
by: Dan Su, et al.
Published: (2023-07-01)

CFX: Contention-Free Channel Access for IEEE 802.11ax
by: Kyu-haeng Lee, et al.
Published: (2022-11-01)

Factors to Consider for the Correct Use of γH2AX in the Evaluation of DNA Double-Strand Breaks Damage Caused by Ionizing Radiation
by: Davide Valente, et al.
Published: (2022-12-01)

The Phosphorylated Form of the Histone H2AX (γH2AX) in the Brain from Embryonic Life to Old Age
by: Adalberto Merighi, et al.
Published: (2021-11-01)

Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α<sub>v</sub>β<sub>3</sub>-Targeted Radionuclide Therapy
by: Guangjie Yang, et al.
Published: (2022-06-01)

Efficacy of <sup>177</sup>Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study
by: Golmehr Sistani, et al.
Published: (2020-12-01)

Complete loss of E-cadherin expression in a rare case of metastatic malignant meningioma: a case report
by: Dominik Lisowski, et al.
Published: (2023-11-01)

Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer
by: Michal Grzmil, et al.
Published: (2022-12-01)

Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
by: Emile B. Veenstra, et al.
Published: (2022-06-01)

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report
by: Ryosuke Umino, et al.
Published: (2024-02-01)

Development of a methodology for the analysis of radionuclide impurities in radiopharmaceuticals by gamma-ray spectrometry
by: Eduardo Bonfim De Paula, et al.
Published: (2017-11-01)